🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Melanoma-associated anxiety can severely affect patients. Providing detailed prognostic information at diagnosis can significantly ease patient anxiety around recurrence and offer a more personalised management schedule. #WorldCancerDay #UnitedByUnique #AMBLor

This Skin Cancer UK campaign really resonated with us and we urge people to avoid using sunbeds. #Melanoma is the deadliest #skincancer. It's very treatable if caught early but your risk can be lowered by protecting your skin from UV damage delivered by the sun or sunbed use.

High #melanoma overdiagnosis isn't due to diagnostic error but the lack of precise tests to differentiate benign Spitz tumours from malignant ones. bit.ly/4grdQ8X Our CATNAP IUK study examined #AMBLor® in classifying and risk determining of atypical, pigmented lesions.

Latest USA cancer statistics state that new cases of #melanoma for 2025 are estimated at 104,960, with 8,430 predicted deaths. Progress in treatment has doubled 5-year relative survival but further investment is also needed into cancer prevention. bit.ly/4gxZOSL#

Calling all UK melanoma patients and family members: Melanoma Focus UK Patient Conference 2025 is taking place 27-28 February in Birmingham, UK. Learn about current research and living well with #melanoma, as well as the opportunity to ask your questions. #mpc2025

Dr Marie labus, our CEO, spoke at the UK Parliamentary Science, Innovation and Technology Committee Showcase on 17 Dec 2024, highlighting our groundbreaking work in #melanoma #diagnostics and the challenges facing small companies in bringing products to the UK healthcare market. Watch: bit.ly/3CVwrMv

Differentiating between benign and malignant melanocytic neoplasms is an issue but PRAME could be a useful immunohistochemical marker. bit.ly/3WKDVIV Similarly our CATNAP study is looking at AMBLor®’s ability to differentiate #melanoma in situ and benign dysplastic naevi

AMLo Biosciences are pleased to have completed the NHS Evergreen Sustainable Supplier Assessment: a self-assessment and reporting tool for us to engage with the NHS on its sustainability journey, understand how we align with NHS net zero and sustainability ambitions. #GreenerNHS

Interesting new research suggests that microglial activation can promote #melanoma brain metastasis. Therefore, microglial reprogramming has the potential to enhance antitumour immunity and improve responses to immunotherapy. bit.ly/42JM6Jt

As reported by The Skin Cancer Foundation 👒 Facts and Statistics, the number of new #melanoma cases in the USA is still rising and an estimated 5.9% increase in diagnosis is expected in 2025. Check your skin regularly for changes. bit.ly/4395ccc

AMLo Biosciences are delighted to be exhibiting again, booth 2281, at the 2025 American Academy of Dermatology congress #AAD25, March 7-11 in Orlando, Florida. Come and talk to the team about #AMBLor®, our prognostic #melanoma test. AADmember

The AMLo Biosciences booth 2281 at #AAD25 is ready! Come along and meet the team to find out more about our innovative biomarker prognostic #AMBLor® and our real-world evidence in identifying early-stage low-risk #melanoma.

#AAD 2025 starts today! Visit our booth 2281. One session explores differentiating benign #melanoma lesions from those prone to metastasise and emerging technologies aiding prognosis. #AMBLor® is our prognostic biomarker test that reliably segments early-stage, low-risk melanomas

Only 1.8% of venture capital in healthtech goes to female-led startups, despite performing significantly better than male counterparts. Our female-founded and run innovative diagnostics company want to challenge this imbalance bit.ly/4bmN40v #IWD2025 #AccelerateAction

Thanks to all who visited us at #AAD25. “Patient-tailored care” is the phrase that resonates with our customers. #AMBLor®, our accurate biomarker prognostic, demonstrates a paradigm shift in #melanoma care from population-based medicine to personalised medicine.

The countdown to the World Congress of Melanoma & EADO Congress has begun, and we’re looking forward to connecting with #melanoma experts from across the world. Come and speak to us at stand #24 and find out about our biomarker test #AMBLor®. amlo-biosciences.com

We can’t wait for next month’s 11th World Congress of Melanoma & 21st EADO Congress where you can find us at Stand #24 if you’d like to find out more about our prognostic biomarker, AMBLor®. The programme includes some interesting sessions on biomarkers for melanoma.

Katherine Ryan's recent second #melamona diagnosis is a stark reminder of the aggressive nature of this #skincancer type. Katherine Ryan contact us to discuss our AMBLor® melanoma risk stratification test. bit.ly/4bYSwXR

We have an abstract and talk on our early research at EADO. A-407: Harnessing machine learning to the immunohistochemical expression of AMBRA1 and Loricrin to identify non-ulcerated AJCC Stage I/II melanomas at high-risk of metastasis. O403: 4 April 16:50 #melanoma

Patient satisfaction and involvement in decision-making are increasingly recognised as critical components of #melanoma care. We recognise that accurate prognostic information plays a vital role in advancing management strategies. #AMBLor® bit.ly/4kTGD9w